S&P 500: 681.75 +0.1% NASDAQ 100: 601.92 +0.2% Dow Jones: 495.28 +0.1%

Renaissance Technologies’s CRL Holdings & Trades

First Buy
Q2 2013
Duration Held
39 Quarters
Largest Add
Q2 2013
+1.18 M Shares
Current Position
10,200 Shares
$2.03 M Value

Renaissance Technologies's CRL Position Overview

Renaissance Technologies (via Renaissance Technologies LLC) currently holds 10,200 shares of Charles River Laboratories International, Inc. (CRL) worth $2.03 M, representing 0.00% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 39 quarters.

Based on 13F filings, Renaissance Technologies has maintained a strategic position in CRL, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2015, adding 416,723 shares. Largest reduction occurred in Q2 2014, reducing 468,309 shares.

Analysis based on 13F filings available since 2013 Q2

Renaissance Technologies's Charles River Laboratories International (CRL) Holding Value Over Time

Track share changes against reported price movement

Quarterly Charles River Laboratories International (CRL) Trades by Renaissance Technologies

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2013 +1.18 M Add 0.00% 1.18 M $41.03
Q3 2013 -278,100 Reduce 23.48% 906,209 $46.26
Q4 2013 -239,500 Reduce 26.43% 666,709 $53.04
Q1 2014 +134,709 Add 20.21% 801,418 $60.34
Q2 2014 -468,309 Reduce 58.44% 333,109 $53.52
Q3 2014 +25,700 Add 7.72% 358,809 $59.74
Q4 2014 +53,800 Add 14.99% 412,609 $63.64
Q1 2015 +416,723 Add 101.00% 829,332 $79.29
Q2 2015 +253,277 Add 30.54% 1.08 M $70.34
Q3 2015 -266,400 Reduce 24.61% 816,209 $63.52
Q4 2015 +56,300 Add 6.90% 872,509 $80.39
Q1 2016 +77,700 Add 8.91% 950,209 $75.94
Q2 2016 -170,100 Reduce 17.90% 780,109 $82.44
Q3 2016 +155,800 Add 19.97% 935,909 $83.34
Q4 2016 +184,300 Add 19.69% 1.12 M $76.19
Q1 2017 -53,700 Reduce 4.79% 1.07 M $89.95
Q2 2017 +153,374 Add 14.38% 1.22 M $101.15
Q3 2017 +119,826 Add 9.82% 1.34 M $108.02
Q4 2017 +58,991 Add 4.40% 1.4 M $109.45
Q1 2018 +61,600 Add 4.40% 1.46 M $106.74
Q2 2018 +55,000 Add 3.77% 1.52 M $112.26
Q3 2018 +209,500 Add 13.83% 1.72 M $134.54
Q4 2018 +152,309 Add 8.83% 1.88 M $113.18
Q1 2019 +8,591 Add 0.46% 1.89 M $145.25
Q2 2019 -221,200 Reduce 11.73% 1.66 M $141.90
Q3 2019 -207,817 Reduce 12.49% 1.46 M $132.37
Q4 2019 -29,104 Reduce 2.00% 1.43 M $152.76
Q1 2020 -90,191 Reduce 6.32% 1.34 M $126.21
Q2 2020 -302,609 Reduce 22.63% 1.03 M $174.35
Q3 2020 -317,100 Reduce 30.64% 717,679 $226.45
Q4 2020 -283,190 Reduce 39.46% 434,489 $249.86
Q1 2021 -254,300 Reduce 58.53% 180,189 $289.83
Q2 2021 -123,389 Reduce 68.48% 56,800 $369.91
Q3 2021 -16,500 Reduce 29.05% 40,300 $412.68
Q4 2021 -13,200 Reduce 32.75% 27,100 $376.79
Q1 2022 +7,309 Add 26.97% 34,409 $283.97
Q2 2022 +44,100 Add 128.16% 78,509 $213.98
Q3 2022 -78,509 Sold Out 0 $0.00
Q4 2025 +10,200 New Buy 10,200 $199.48

Renaissance Technologies's Charles River Laboratories International Investment FAQs

Renaissance Technologies first purchased Charles River Laboratories International, Inc. (CRL) in Q2 2013, acquiring 1,184,309 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Renaissance Technologies has held Charles River Laboratories International, Inc. (CRL) for 39 quarters since Q2 2013.

Renaissance Technologies's largest addition to Charles River Laboratories International, Inc. (CRL) was in Q2 2013, adding 1,184,309 shares worth $48.59 M.

According to the latest 13F filing for Q4 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 10,200 shares of Charles River Laboratories International, Inc. (CRL), valued at approximately $2.03 M.

As of the Q4 2025 filing, Charles River Laboratories International, Inc. (CRL) represents approximately 0.00% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings.

Renaissance Technologies's peak holding in Charles River Laboratories International, Inc. (CRL) was 1,885,700 shares, as reported at the end of Q1 2019.